Ultragenyx Pharmaceutical... (RARE)
| Bid | 33.86 |
| Market Cap | 3.28B |
| Revenue (ttm) | 560.23M |
| Net Income (ttm) | -569.18M |
| EPS (ttm) | -6.29 |
| PE Ratio (ttm) | -5.55 |
| Forward PE | -8.47 |
| Analyst | Buy |
| Ask | 44.5 |
| Volume | 848,494 |
| Avg. Volume (20D) | 807,526 |
| Open | 35.04 |
| Previous Close | 34.14 |
| Day's Range | 33.81 - 35.10 |
| 52-Week Range | 29.59 - 60.37 |
| Beta | 0.61 |
About RARE
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia...
Analyst Forecast
According to 14 analyst ratings, the average rating for RARE stock is "Buy." The 12-month stock price forecast is $84.5, which is an increase of 142.19% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
Ultragenyx Pharmaceutical Inc. (RARE) Q4 2024 Earnings Call TranscriptUltragenyx Pharmaceutical Inc. (NASDAQ:RARE ) Q4 2024 Earnings Conference Call February 13, 2025 5:00 PM ET Company Participants Joshua Higa - VP, IR Emil Kakkis - CEO and President Erik Harris - CCO ...
